Navigation Links
Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
Date:4/29/2013

ations (industry, academia, government) that can lead to the advancement of therapeutics and development of drugs/treatments for diabetes, and hopefully one day a cure. In addition the conference will provide updated educational research on various novel targets, therapeutics, developments, and technologies; regulatory guidance; case studies on successful and/or unsuccessful clinical trials; and other relevant insights that can help delegates advance their own research and therapeutics. 

For more information on the Summit, please visit their website at http://www.gtcbio.com/conference/diabetes-summit-overview

About Oramed Pharmaceuticals  

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently approaching Phase 2 clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit  http://www.oramed.com.

The company's fact sheet, the content of which is not part of this press release, can be viewed here.

Forward-looking statements: This press re
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Oramed Pharmaceuticals Chosen to Present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria; April 18-20, 2013
2. Oramed Pharmaceuticals Appoints New Chief Operating Officer and VP of Business Development
3. Oramed Submits New IND Application for Oral Insulin Trial in the US
4. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
5. Oramed Pharmaceuticals to Present at the 4th Annual Drug Delivery & Formulation Summit in Berlin
6. Shares of Oramed Pharmaceuticals Are Approved for Listing on the Nasdaq Capital Market
7. Oramed Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on February 7th
8. Oramed Pharmaceuticals Completes $5.6 Million Funding to Advance Clinical Trials
9. Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
10. Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand
11. Oramed Pharmaceuticals to Present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference; Tel Aviv, Israel, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... New Zealand , July 28, 2014 /PRNewswire/ ... in Sweden has validated ... multiple vendor platforms and has associated volumetrically assessed ... in Cancer Epidemiology, Biomarkers & Prevention ... mammographic density: a tool for widespread breast cancer ...
(Date:7/28/2014)... July 28, 2014  ALPHAEON Corporation ... healthcare and subsidiary of Strathspey Crown ... Recommended Nutriceuticals (PRN) ® , a leading ... products for dry eye and macular ... transaction worth up to $55M. ...
(Date:7/28/2014)... July 28, 2014 ... 2,5 Millionen £ investiert hat, um die ... Gesundheits-, Pharma- und Logistikbranche zu erfüllen. Albion ...      (Photo: http://photos.prnewswire.com/prnh/20140728/697982 ) ... OmPrompt sein beschleunigtes Wachstum mit Investitionen in ...
Breaking Medicine Technology:Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 2ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 3OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2
... PharmaMar SA (Grupo Zeltia, ZEL.MC) has announced ... for patients with solid tumors. PM060184 is a marine-derived, synthetically-produced ... in vivo antitumor activity and a favorable safety ... in clinical development. The trials will be performed ...
... Feb. 7, 2011 Pharmasset, Inc. (Nasdaq: ... discovering, developing, and commercializing novel drugs to treat viral ... the quarter ended December 31, 2010. ... ended December 31, 2010 compared to $0.3 million for ...
Cached Medicine Technology:PharmaMar Commences Clinical Trial in U.S. with New Antitumor Product, PM060184 2Pharmasset Reports Fiscal First Quarter 2011 Financial Results 2Pharmasset Reports Fiscal First Quarter 2011 Financial Results 3Pharmasset Reports Fiscal First Quarter 2011 Financial Results 4Pharmasset Reports Fiscal First Quarter 2011 Financial Results 5Pharmasset Reports Fiscal First Quarter 2011 Financial Results 6
(Date:7/28/2014)... July 29, 2014 “China Surgical ... data on the China Surgical Generators market. The ... volume (in units) and average prices (in US ... Generators, Ultrasonic Generators and Argon Plasma Coagulation Generators. ... distribution shares data for each of these market ...
(Date:7/28/2014)... Heights, MI (PRWEB) July 28, 2014 ... UHY, introduces the latest edition of UHY International Business ... provided by our members, on the most current business ... around the world. Issue 29 covers the following topics:, ... growth: Which industry sectors will thrive over the next ...
(Date:7/28/2014)... Randy Dotinga HealthDay Reporter ... know it takes humans just milliseconds to look at someone,s ... a new study finds that certain facial features seem to ... The shape and size of the mouth, for example, appear ... are keys to attractiveness. The study findings suggest ...
(Date:7/28/2014)... July 28, 2014 Thousands of DePuy ... behalf of individuals who were allegedly injured by a ... to move forward in U.S. District Court, Northern District ... Order issued on July 18, 2014, U.S. District Judge ... by the Plaintiffs’ Steering Committee that sought the deposition ...
(Date:7/28/2014)... Ticket Down is a dependable source for cheap ... the Sun Life Stadium in early September. The decades ... has is one that has continues to go on. With ... a consistent basis. The rivalry between South America nations, ... 2014 World Cup. To the delight of soccer aficionados ...
Breaking Medicine News(10 mins):Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 2Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 3Health News:Key Market Data on China Surgical Generators Market to 2020 Report Available at MarketOptimizer.org 4Health News:Uhy International Business Issue 29 Now Available 2Health News:Uhy International Business Issue 29 Now Available 3Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 2Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 3
... researcher at The University of Texas Health Center at ... of the blood-clotting process works. Once the process// is ... it, thus preventing excessive bleeding or blood clotting. The ... published in the Aug. 11, 2006, edition of the ...
... tuberculosis, precautionary letters have been sent to 500 people ... the// disease. The condition of the patient suffering ... ,The patient was diagnosed with active form ... diseases unit at Aberdeen Royal Infirmary from Aberdeen's Woodend ...
... who advice patients to give up smoking may be more ... according to a new study in the July-August 2006// Nursing ... recognized as central to global efforts to reduce the detrimental ... Nursing Research editor and professor of nursing at the University ...
... An MRI-guided breast biopsy successfully removed the breast lesion ... slices of the lesion, according to radiologists. "Contrast-enhanced// MRI ... with lesions that cannot be detected with other techniques," ... the University of Texas M.D. Anderson Cancer Center in ...
... as a hazard of aging, but researchers actually do ... aging// or not. Researchers at the Salk Institute for ... conducted a study that proves it is aging that ... beta amyloid aggregates accumulate when aging impedes two molecular ...
... Dr. Morey Haymond, chief of paediatric endocrinology at Texas Children's ... tale signs of diabetes in children. , ,Children ... a bit more independent, hence parents many not be able ... 2 diabetes is more an affliction with the obese and ...
Cached Medicine News:Health News:Scientist Discovers Crucial Part of Blood-Clotting Process 2Health News:Nurses Can Play Big Role In Helping Patients Quit Smoking 2Health News:MRI-guided Breast Biopsy Pronounced a Success 2Health News:Aging Critical For Alzheimer's Disease 2Health News:Aging Critical For Alzheimer's Disease 3
The design of this table top is based on advanced functionality for specific urological requirements. This composite product sets a new standard for urological imaging....
Drew Scientific has been making leading edge and top quality CBC systems for over 15 years.,The Excell 16/18 offers a reliable alternative for a 3 part differential....
... Heavy Duty is a pressure relief mattress overlay ... specifically to the BariKare® Bed., ,INDICATIONS , ... lbs., Large patients at risk or suffering from ... mattress that would benefit from a pressure relief ...
... is a healthcare bed system which helps ... the home care setting, ,INDICATIONS: ,Patients ... of 2) ,Healthcare frame accommodating one ... selected, ,CONTRAINDICATIONS: ,Total weight in excess ...
Medicine Products: